External Ventricular Drain

Quick Answer

An external ventricular drain (EVD), also known as a ventriculostomy, is a temporary catheter placed into the lateral ventricle for simultaneous intracranial pressure monitoring and cerebrospinal fluid drainage. The gold standard for ICP management, EVDs are indicated for acute hydrocephalus, refractory raised ICP, and intraventricular hemorrhage clearance. Catheters are typically placed at Kocher's point (2.5 cm lateral to midline, 11 cm posterior to nasion) using freehand or image-guided technique, aiming for the contralateral frontal horn. Drain settings are referenced to the external auditory meatus, typically set between -5 to +10 cmH₂O for continuous or intermittent drainage. Key complications include ventriculitis (5-15%), hemorrhage (1-5%), catheter misplacement (10-15%), and obstruction. Antibiotic-impregnated catheters, strict aseptic technique, and minimal system manipulation reduce infection risk. Weaning involves clamp trials for 24-48 hours with clinical and ICP monitoring; failure requires conversion to permanent ventriculoperitoneal shunt.

CICM Second Part Exam Focus

Critical Knowledge Areas

High-Yield Clinical Scenarios

1. Post-SAH hydrocephalus: Communicating hydrocephalus requiring EVD for CSF diversion and ICP control
2. Traumatic brain injury: Refractory raised ICP (greater than 22 mmHg) despite first-tier measures
3. Intraventricular hemorrhage: Clearance of blood from ventricular system, tPA use controversy
4. EVD infection: Fever with CSF pleocytosis, organism identification, catheter management
5. EVD obstruction: Sudden ICP rise, troubleshooting steps, catheter replacement indications

Differential Diagnosis

Raised ICP with EVD in place:

• Catheter obstruction (most common acute cause)
• Ventriculitis/meningitis
• Catheter misplacement (tip in parenchyma)
• Over-drainage causing subdural hematoma
• Progressive cerebral edema or new hemorrhage

Key Points

Clinical Overview

Definition and Purpose

An external ventricular drain (EVD), also known as a ventriculostomy, is a temporary catheter system that provides simultaneous intracranial pressure (ICP) monitoring and therapeutic cerebrospinal fluid (CSF) drainage. The EVD remains the gold standard for ICP management in neurocritical care, offering advantages over other monitoring devices including the ability to drain CSF, recalibration capability, and direct ventricular pressure measurement.

EVDs are critical devices in the management of life-threatening neurological conditions, particularly:

• Acute hydrocephalus from various etiologies
• Refractory intracranial hypertension
• Intraventricular hemorrhage requiring blood clearance
• Therapeutic CSF diversion in meningitis or ventriculitis

Epidemiology

EVD placement is one of the most common neurosurgical procedures in intensive care units worldwide. The incidence varies by clinical setting:

The average duration of EVD catheterization ranges from 5 to 14 days, with prolonged use (greater than 21 days) associated with significantly increased complication rates, particularly infection.

Procedural Statistics

Technical success rates:

• First-pass cannulation: 60-75%
• Overall successful placement: greater than 95%
• Malplacement rate requiring repositioning: 10-15%

Complication rates:

• Overall complication rate: 20-35%
• Clinically significant complications: 5-10%
• Mortality directly attributable to EVD: below 1%

Historical Context

The external ventricular drain concept dates to the early 20th century:

• 1914: Harvey Cushing first described ventricular puncture
• 1950s-60s: Development of continuous pressure monitoring systems
• 1970s: Introduction of modern closed drainage systems
• 1990s: Antibiotic-impregnated catheters developed
• 2000s-present: Image-guided navigation and standardised protocols

The evolution of EVD technology has transformed it from a high-risk procedure to a relatively safe, essential tool in modern neurocritical care.

Anatomy Relevant to EVD Placement

Ventricular System

The lateral ventricles are the primary targets for EVD catheter placement due to their accessibility and size.

Foramen of Monro: The critical landmark connecting the lateral ventricles to the third ventricle. Located approximately 11 cm posterior to the nasion at the midline. The EVD transducer is levelled to approximate this point (external auditory meatus).

Kocher's Point: The Primary Entry Site

Kocher's point is the standard entry point for frontal EVD placement, described by Theodor Kocher in 1893.

Coordinates:

• Lateral: 2.5-3 cm from midline (in adults)
• Anterior-posterior: 11 cm posterior to nasion (glabella)

Anatomical relationships:

• Located in the prefrontal cortex (non-eloquent brain)
• Anterior to the motor cortex (precentral gyrus)
• Posterior to the frontal sinus
• Avoids the superior sagittal sinus and bridging veins

Surgical considerations:

• Avoids major cortical veins
• Minimises risk of eloquent cortex injury
• Provides direct trajectory to frontal horn of lateral ventricle
• Perpendicular trajectory (aiming toward foramen of Monro) recommended

Alternative Entry Points

Critical Neurovascular Structures

Structures to avoid during catheter advancement:

1. Bridging veins:

   • Drain superficial cortex into superior sagittal sinus
   • Injury causes subdural hematoma
   • Located more posteriorly in parasagittal region

2. Middle cerebral artery (MCA) branches:

   • Located laterally in Sylvian fissure
   • Excessive lateral trajectory risks injury

3. Choroid plexus:

   • Vascular structure in ventricular body
   • Catheter contact causes obstruction or hemorrhage

4. Basal ganglia/internal capsule:

   • Medial to ventricular trajectory
   • Deep penetration risks eloquent brain injury

Ventricular Size Considerations

Normal ventricular dimensions:

• Frontal horn width: below 10 mm at midline
• Evans ratio: Frontal horn distance/inner skull width below 0.3

Dilated ventricles (easier EVD placement):

• Hydrocephalus with Evans ratio greater than 0.3
• Acute hydrocephalus (SAH, IVH)
• Chronic communicating hydrocephalus

Slit/collapsed ventricles (challenging):

• Severe brain edema
• Mass effect with midline shift
• May require image guidance or alternative approaches

Indications for External Ventricular Drain

Primary Indications

1. Acute Hydrocephalus

Obstructive (Non-communicating) Hydrocephalus:

• Posterior fossa tumors compressing fourth ventricle
• Aqueductal stenosis (congenital or acquired)
• Intraventricular tumors obstructing foramen of Monro
• Posterior fossa hemorrhage with fourth ventricle obstruction

Communicating Hydrocephalus:

• Aneurysmal subarachnoid hemorrhage (aSAH) - most common indication
• Meningitis (bacterial, tuberculous, fungal)
• Intraventricular hemorrhage with blood obstructing CSF absorption
• Post-traumatic hydrocephalus (weeks after injury)

Clinical presentation:

• Progressive headache, nausea, vomiting
• Decreased level of consciousness (GCS deterioration)
• Papilledema, Cushing's triad (late)
• Upward gaze palsy (Parinaud syndrome - posterior fossa lesions)

2. Intracranial Pressure Monitoring and Management

Indications for ICP monitoring (Brain Trauma Foundation guidelines):

• Severe TBI (GCS 3-8) after resuscitation
• Abnormal CT (hematoma, contusion, swelling, herniation) OR
• Normal CT with ≥2 of: age greater than 40, unilateral/abnormal motor posturing, SBP below 90 mmHg

EVD vs Parenchymal Monitor:

3. Intraventricular Hemorrhage Clearance

Primary IVH:

• Spontaneous hypertensive IVH
• Hemorrhage extending into ventricular system
• Associated with higher mortality than parenchymal bleeds alone

Therapeutic rationale:

• Reduces ICP by removing blood mass
• Prevents obstructive hydrocephalus from blood clots
• May reduce toxic effects of blood products on brain parenchyma

Controversy: Intraventricular tPA:

• CLEAR III trial: IV tPA for IVH showed faster clot clearance and improved mRS 3-6 (though not primary endpoint)
• MISTIE III: Combined minimally invasive surgery + tPA showed improved functional outcomes
• Current practice varies by institution

4. Ventriculitis and Meningitis

Therapeutic CSF drainage:

• Facilitates removal of infected CSF
• Allows intrathecal antibiotic administration
• Provides diagnostic samples for culture and sensitivity

Indications:

• Healthcare-associated ventriculitis/meningitis
• Culture-proven CSF infection
• Elevated ICP secondary to infection

5. Normal Pressure Hydrocephalus Trial

Diagnostic indication:

• Classic triad: gait disturbance, urinary incontinence, dementia
• Large-volume lumbar tap test (30-50 mL CSF removal)
• If no improvement or contraindication to lumbar puncture → EVD trial

Trial protocol:

• EVD placed for 3-5 days
• Gradual weaning with clinical assessment
• Positive response → consideration for VP shunt
• Negative response → search for alternative diagnosis

Relative Indications

1. Postoperative CSF leak:

   • Following skull base surgery
   • Allows healing of dural defect

2. Intraoperative brain relaxation:

   • During craniotomy for tumor/aneurysm clipping
   • Facilitates surgical exposure

3. Pseudotumor cerebri (IIH):

   • Temporary CSF diversion for severe papilledema
   • Bridge to definitive management

Contraindications

Absolute contraindications:

• Severe coagulopathy (INR greater than 1.5, platelets below 50,000/μL) - must correct first
• Localized infection at insertion site

Relative contraindications:

• Significant midline shift (greater than 1 cm) - contralateral ventricle compressed
• Small/collapsed ventricles without image guidance
• Hemorrhagic diathesis or ongoing bleeding
• Severe thrombocytopenia (platelets below 100,000/μL) - increased hemorrhage risk

Special considerations:

• Anticoagulation: Hold and reverse if possible
• Antiplatelet therapy: Increased hemorrhage risk, weigh benefits/risks
• Renal failure with uremic platelet dysfunction: May require dialysis first

Technique: External Ventricular Drain Placement

Pre-Procedural Preparation

Patient positioning:

• Supine with head neutral or slightly flexed
• Head may be turned 15-30° to contralateral side (right-sided approach typical)
• Immobilisation with three-point Mayfield pin fixation (if in OR) or head holder
• Ensure cervical spine alignment if TBI or neck injury suspected

Monitoring:

• Standard ASA monitors (ECG, SpO₂, NIBP)
• Arterial line for beat-to-beat blood pressure
• Consider invasive neuromonitoring (EEG, SSEP) for complex cases
• Capnography if sedated

Imaging:

• CT scan within 24 hours (immediate if possible)
• Assess ventricular size, midline shift, trajectory path
• Identify hemorrhage, skull fractures, or tumors
• Plan entry point and target

Coagulation optimisation (if possible):

• INR correction with vitamin K and/or PCC (target below 1.3-1.5)
• Platelet transfusion if below 50,000-100,000/μL
• Hold anticoagulants (warfarin, DOACs, heparin) as appropriate
• Consider antiplatelet reversal (platelet transfusion) if recent aspirin/clopidogrel

Insertion Technique: Freehand Method

Step 1: Site preparation and draping

• Shave hair (typically right frontal region)
• Antiseptic skin preparation (chlorhexidine-alcohol or povidone-iodine)
• Full sterile barrier: sterile gown, gloves, mask, eye protection
• Large sterile drape with opening at planned entry site

Step 2: Local anaesthesia

• Infiltrate lidocaine 1% with epinephrine along incision line
• Extend to periosteum
• Consider additional sedation if patient agitated (avoid excessive sedation in TBI)

Step 3: Incision and burr hole

• Curvilinear or linear incision at Kocher's point
• Scalpel through skin, subcutaneous tissue, galea
• Use self-retaining retractor or hooks
• Periosteal elevator to expose skull
• Burr hole drill (hand drill or power drill) perpendicular to skull
• Ensure full penetration through inner table
• Wax bleeding bone edges
• Dura: Coagulate with bipolar, cruciate incision with scalpel/blade

Step 4: Catheter insertion

• Choose appropriate ventricular catheter (standard, antibiotic-impregnated, or silver-coated)
• Trajectory: Aim toward ipsilateral medial canthus (or nasion) and ipsilateral tragus
• Perpendicular to cortical surface (not angled)
• Gently advance catheter:
  • "First 1-2 cm: through cortex"
  • "Next 2-3 cm: through white matter"
  • "At approximately 5-6 cm: expect CSF return"
• Multiple passes: Each additional pass increases hemorrhage risk

Step 5: Catheter confirmation and fixation

• Free-flowing CSF: Confirm clear or bloody (expected in IVH) fluid
• Measure depth from skin to ventricle (typically 5-7 cm)
• Secure catheter:
  • Suture to scalp with non-absorbable suture (e.g., nylon 3-0)
  • Consider tunneling catheter subcutaneously (3-5 cm from burr hole) to reduce infection risk
  • Connect to drainage system with sterile technique

Step 6: Post-procedural imaging

• Immediate CT scan (within 1-2 hours) to confirm:
  • "Catheter tip position (ideal: contralateral frontal horn)"
  • Absence of new hemorrhage along trajectory
  • Adequate CSF drainage
• Re-adjust if malpositioned or no CSF flow

Image-Guided Navigation

Indications for navigation:

• Small or slit ventricles
• Significant midline shift or distorted anatomy
• Previous craniotomy or skull defects
• Trainee education (improves accuracy)

Navigation modalities:

Evidence for navigation:

• Reduces number of passes (median 1 vs 2-3 freehand)
• Higher first-pass success rate (85% vs 60%)
• Lower malplacement rate (5% vs 10-15%)
• May reduce hemorrhage complications (fewer passes)
• However, no mortality benefit demonstrated in most studies

Drainage System Setup

Components:

1. Ventricular catheter - Connected via tubing
2. Pressure transducer - Converts fluid pressure to electrical signal
3. Drip chamber - Visual CSF flow, allows manual drainage
4. Drainage bag - CSF collection
5. Stopcocks - Allow sampling, flushing, system closure
6. Three-way tap - For connection to monitor and drainage

System priming:

• Flush tubing and transducer with sterile saline
• Remove all air bubbles (cause inaccurate readings)
• Connect to patient catheter with aseptic technique

Transducer levelling:

• Reference point: External auditory meatus (tragus) approximates foramen of Monro
• Level transducer to this point
• Mark level on bed frame for consistent positioning
• Re-level after any patient position changes

Zeroing:

• Open system to atmosphere (remove patient connection)
• Set monitor to zero
• Reconnect to patient
• Re-zero daily or after transducer changes

Antibiotic Prophylaxis

Periprocedural antibiotics (consensus recommendation):

• Cefazolin 2 g IV (or 3 g if greater than 120 kg) within 60 minutes before incision
• Repeat for procedures greater than 4 hours or if significant blood loss
• Alternative for penicillin allergy: Vancomycin 15-20 mg/kg (max 2 g) infused over 1-2 hours

Duration:

• Single dose (≤24 hours) is standard
• Prolonged antibiotics (greater than 24 hours) do NOT reduce infection rates
• May increase risk of resistant organisms and C. difficile

Antibiotic-impregnated catheters:

• Rifampin + minocycline OR rifampin + clindamycin
• Reduce infection rates by 50-75%
• Cost-effective despite higher catheter cost
• Recommended for all EVD insertions when available

EVD Management and Drainage Protocols

Drainage Level Settings

Physiologic principles:

• Normal ICP: 5-15 mmHg (equivalent to 7-20 cmH₂O)
• Elevated ICP threshold for intervention: greater than 20-22 mmHg for greater than 5 minutes
• ICP greater than 20-25 mmHg associated with worse outcomes in TBI

Level settings relative to tragus:

Conversion notes:

• 1 cmH₂O ≈ 0.74 mmHg
• 1 mmHg ≈ 1.36 cmH₂O
• Therefore, 10 cmH₂O ≈ 7.4 mmHg

Practical adjustment:

• Start at 0 cmH₂O
• Adjust based on ICP trends and clinical response
• Avoid rapid changes (greater than 5 cmH₂O at a time)
• Document all level changes with time and rationale

Continuous vs Intermittent Drainage

Continuous drainage:

• CSF drains continuously whenever ICP exceeds set level
• Advantages: Simpler, automatic ICP control
• Disadvantages: Higher risk of over-drainage, subdural hematoma

Intermittent drainage:

• Drain opened for set time periods (e.g., 5-10 minutes) when ICP elevated
• Requires nursing attention to open/close drain
• Advantages: Lower over-drainage risk
• Disadvantages: Labor-intensive, ICP may fluctuate between drainage periods

Common protocol (many centres):

• Interconnected system: Drain open when ICP greater than 20 mmHg for greater than 5 minutes
• Close drain when ICP falls below threshold
• Maximum drainage rate typically limited (e.g., 15-20 mL/hour)

Over-drainage complications:

• Slit ventricle syndrome: Ventricles collapse, catheter obstructs
• Subdural hematoma: Bridging vein tearing from brain shift
• Intracranial hypotension: Headaches, nausea, postural worsening
• Precipitating factors: Excessive negative pressure, upright positioning

ICP Waveform Analysis

Normal ICP waveform components:

• P1 (Percussion wave): Systolic arterial pulsation, dominant peak, represents choroid plexus arterial inflow
• P2 (Tidal wave): Early diastolic, represents brain tissue compliance, normally lower than P1
• P3 (Dicrotic wave): Dicrotic notch from aortic valve closure

Pathological patterns:

• Lundberg A waves (plateau waves): Sudden rise to 50-80 mmHg, lasting 5-20 minutes, indicates reduced compliance
• Lundberg B waves: Rhythmic oscillations 0.5-2 Hz, indicates unstable ICP
• Elevated P2 > P1: Reduced compliance, "tall and sharp" wave
• Dampened waveform: Catheter obstruction or kinking

Waveform artefacts:

• Transmission artefact: External pressure on tubing, patient movement
• Air bubbles: Oscillating air causing waveform irregularities
• Transducer malposition: Levelling errors cause pressure offset
• Catheter blockage: Absence of waveform or flat line

CSF Sampling Protocol

Indications for CSF sampling:

• Fever (greater than 38°C) of unclear origin
• New neurological deterioration
• Suspected ventriculitis/meningitis
• Monitoring of intraventricular tPA clearance
• Routine surveillance (controversial - many centres avoid routine daily sampling)

Sampling technique:

1. Prepare: Clean stopcock connection with chlorhexidine/alcohol swab
2. Clamp drain below sampling port
3. Disconnect: Open stopcock to air briefly to clear tubing
4. Collect: Using sterile syringe, aspirate required volume (1-3 mL)
5. Reconnect: Close stopcock to air, reopen drain connection
6. Process: Send for cell count, glucose, protein, culture, Gram stain

Frequency:

• Routine daily sampling: NOT recommended (increases infection risk)
• Sample only when clinically indicated
• Minimise number of entries into closed system

Normal CSF parameters:

• Opening pressure: 10-20 cmH₂O (supine)
• WBC: 0-5/μL (lymphocytes predominant)
• RBC: 0/μL
• Protein: 15-45 mg/dL
• Glucose: 40-70 mg/dL (≈2/3 serum glucose)

Ventriculitis CSF findings:

• WBC: Often greater than 100/μL, neutrophil predominance
• Protein: greater than 100 mg/dL
• Glucose: below 40 mg/dL or below 0.4× serum
• Culture: Positive organism (confirming diagnosis)

Troubleshooting Common Problems

No CSF flow despite catheter in ventricle:

High ICP despite drainage:

• Inadequate drainage level - lower set point
• Catheter obstruction - troubleshoot as above
• New hemorrhage or mass effect - urgent CT
• Cerebral edema - consider osmotherapy, hyperventilation, sedation
• CSF production exceeds drainage - consider additional drain

Low/negative ICP:

• Over-drainage - raise drainage level
• Transducer levelling error - re-level to tragus
• Air in system - flush out air bubbles
• Hypovolemia - optimize volume status

Sudden waveform loss:

• Disconnection - check all connections
• Transducer failure - replace transducer
• Cable disconnected - check monitor cables
• Catheter blockage - attempt flushing or replacement

Complications of External Ventricular Drainage

Overview of Complication Rates

Infectious Complications

Ventriculitis and Meningitis

Definition: Infection of the ventricular system and/or meninges associated with EVD catheter

Incidence: 5-15% of EVDs, decreasing with antibiotic-impregnated catheters and standardised protocols

Risk factors:

Causative organisms:

Clinical presentation:

• Fever (greater than 38°C) - most common sign
• Neck stiffness - meningismus
• Altered mental status - confusion, decreased GCS
• Headache, photophobia
• Erythema or purulence at catheter site

Diagnostic criteria (CDC):

• Definite ventriculitis: CSF culture positive + clinical symptoms + CSF pleocytosis
• Probable ventriculitis: Clinical symptoms + CSF pleocytosis without positive culture (prior antibiotics)

CSF analysis findings:

Treatment:

1. Catheter management:

   • Immediate removal is generally recommended for definite ventriculitis
   • May replace with new EVD on contralateral side if continued drainage needed
   • If removal not possible (ongoing hydrocephalus), may treat through existing catheter with intrathecal antibiotics

2. Empiric systemic antibiotics (before culture results):

   • Vancomycin 15-20 mg/kg q8-12h (target trough 15-20 mg/L) for Gram-positive coverage
   • Ceftazidime 2 g q8h OR Cefepime 2 g q8h OR Meropenem 2 g q8h for Gram-negative coverage
   • Adjust based on culture and sensitivity

3. Intrathecal antibiotics (if needed):

   • Vancomycin 10-20 mg daily (via EVD)
   • Gentamicin 1-2 mg daily
   • Colistin 125,000 IU daily
   • Reserved for organisms with poor CSF penetration or resistant infections

4. Duration:

   • 10-14 days for uncomplicated ventriculitis
   • 14-21 days for Gram-negative or resistant organisms
   • Continue until:
     • Clinically improved (afebrile greater than 48h)
     • CSF WBC below 50/μL and decreasing
     • CSF culture negative for ≥48h

Prognosis:

• Mortality: 5-10% (higher in elderly, Gram-negative infections)
• Neurologic sequelae: 15-20% (cognitive deficits, seizures)
• Full recovery: 70-80% with appropriate treatment

Preventive Strategies

Bundle approach (Neurocritical Care Society recommendations):

1. Antibiotic-impregnated catheters: First-line when available
2. Periprocedural antibiotics: Single dose cefazolin 2 g IV within 60 min of incision
3. Full sterile barrier: Cap, mask, sterile gown, gloves, large drapes
4. Chlorhexidine-alcohol skin preparation: Superior to povidone-iodine
5. Subcutaneous tunneling: Minimum 3-5 cm from burr hole
6. Closed system maintenance: Minimise entries, use sterile technique for all manipulations
7. Avoid routine catheter exchange: No benefit, increased risk
8. Avoid routine CSF sampling: Sample only when clinically indicated
9. Dressings: Semi-permeable transparent dressing, change weekly or if soiled

Evidence for interventions:

• Antibiotic-impregnated catheters: 50-75% relative risk reduction (multiple meta-analyses)
• Periprocedural antibiotics: Modest benefit, no additional benefit with prolonged use
• Silver-coated catheters: Less effective than antibiotic-impregnated
• Prophylactic catheter exchange: No infection reduction, increases complications

Hemorrhagic Complications

Incidence and Risk Factors

Total hemorrhage rate: 10-40% (includes microscopic track hemorrhage) Symptomatic hemorrhage: 1-5% Significant hemorrhage requiring intervention: 1-2%

Risk factors:

Types of hemorrhage:

1. Track hemorrhage: Along catheter trajectory

   • Most common type
   • Usually small, asymptomatic
   • Visible on post-procedure CT

2. Intraventricular hemorrhage:

   • New or increased IVH
   • May cause catheter obstruction
   • Associated with worse outcomes if large

3. Intraparenchymal hemorrhage:

   • Remote from trajectory
   • May be due to vascular injury
   • Rare (below 1%)

4. Epidural hemorrhage:

   • Burr hole site bleeding
   • Usually from dural or bone edges
   • Requires evacuation if symptomatic

5. Subdural hemorrhage:

   • Usually from over-drainage (bridging vein tear)
   • Not related to insertion technique per se

Management of Hemorrhagic Complications

Asymptomatic track hemorrhage:

• Observation
• Continue EVD if functioning
• Repeat CT in 24-48 hours to ensure stability
• Monitor neurologic status closely

Symptomatic hemorrhage:

1. Immediate assessment:

   • ABCs, hemodynamic stability
   • GCS assessment, pupillary exam
   • Urgent CT scan

2. Medical management:

   • Reverse any coagulopathy:
     • Warfarin: PCC + Vitamin K
     • DOACs: Specific reversal agents (idarucizumab, andexanet) if available
     • Antiplatelets: Platelet transfusion (especially if recent clopidogrel/ticagrelor)
   • Control hypertension (SBP below 140 mmHg if significant bleed)
   • Maintain normovolemia

3. Surgical considerations:

   • Evacuation: If hematoma causing mass effect, midline shift, or neurological deterioration
   • EVD management: May keep for ICP control, consider new catheter if original obstructed
   • Craniotomy: For large parenchymal or subdural hematomas

Hemorrhage prevention:

• Optimise coagulation status before placement
• Minimise number of passes
• Consider image guidance for difficult cases
• Avoid excessive catheter manipulation
• Control peri-procedural blood pressure

Catheter Malposition

Definition: Catheter tip not in intended ventricular location

Incidence: 10-15%

Types of malposition:

1. Intraparenchymal: Tip in brain tissue

   • Most common malposition
   • May cause obstruction, no CSF return
   • May cause local brain injury

2. In contralateral ventricle: Rare with proper technique

   • Usually acceptable if functioning
   • May need adjustment if not draining properly

3. In third ventricle: Over-penetration

   • Risk of hypothalamic or brainstem injury
   • May cause endocrine disturbances

4. In subarachnoid space:

   • May still drain CSF but less controlled
   • Higher infection risk

Causes of malposition:

• Inaccurate trajectory
• Midline shift (target displaced)
• Small/collapsed ventricles
• Anatomical variations
• Patient movement during insertion

Detection:

• No CSF return during placement
• Poor ICP waveform after connection
• Post-procedure CT: Catheter tip location confirmed

Management:

• Non-functioning: Remove and replace with new catheter
• Functioning but malpositioned: May leave in place if draining adequately
• Significantly malpositioned: Replace with new catheter

Catheter Obstruction

Incidence: 10-20%

Causes:

Clinical presentation:

• Sudden rise in ICP
• Loss of waveform
• Inability to aspirate CSF
• No drainage despite ICP above set level

Troubleshooting:

1. Check all connections: Ensure no disconnections or kinks
2. Check transducer: Ensure proper function and levelling
3. Attempt gentle aspiration: Using 0.5-1 mL sterile syringe
4. Gentle flushing: With 0.5-1 mL sterile saline (controversial - may introduce infection)
5. Catheter repositioning: If within first 24h, may attempt to withdraw slightly
6. Catheter replacement: If unable to clear obstruction

Prevention:

• Avoid placing tip in choroid plexus
• Gentle handling during insertion
• Avoid excessive manipulation
• Prompt management of IVH (may consider tPA in selected cases)

Over-Drainage Complications

Subdural hematoma:

• Incidence: 1-3%
• Mechanism: Rapid CSF drainage causes brain to collapse away from skull, tearing bridging veins
• Risk factors: Excessive negative drainage pressure, upright positioning, elderly, brain atrophy
• Presentation: Headache, confusion, focal neurologic deficit, seizures
• Diagnosis: CT scan (hyperdense crescent-shaped collection)
• Management:
  • Raise drainage level immediately
  • Observe if small and asymptomatic
  • Surgical evacuation if symptomatic or causing mass effect

Slit ventricle syndrome:

• Incidence: 2-5% in long-term shunt patients, rare with temporary EVDs
• Mechanism: Ventricles collapse around catheter, causing obstruction and intermittent ICP elevation
• Presentation: Headaches, nausea, may mimic shunt malfunction
• Management: Raise drainage level, may require catheter replacement

Intracranial hypotension:

• Symptoms: Headache (worse upright), nausea, diplopia, tinnitus
• Management: Raise drainage level, keep patient supine, hydrate, consider epidural blood patch (rarely needed for EVD)

Pneumocephalus

Incidence: 5-10% (usually minimal)

Types:

1. Simple pneumocephalus:

   • Small air bubbles, usually resolves spontaneously
   • Common after EVD placement
   • No treatment required

2. Tension pneumocephalus (RARE, EMERGENCY):

   • Air under pressure causing mass effect
   • "Mount Fuji sign" on CT: Compressed frontal lobes with peaked appearance
   • Symptoms: Headache, confusion, decreased consciousness, uncal herniation signs
   • Treatment: Needle decompression (burr hole) or urgent craniotomy

Prevention:

• Keep patient supine after placement
• Avoid excessive drainage before complete seal
• Ensure all connections are airtight

Weaning and Removal of External Ventricular Drain

Indications for Weaning

Clinical improvement:

• Underlying pathology resolving (edema decreasing, hydrocephalus improving)
• ICP consistently normal (below 15-20 mmHg) despite minimal/no drainage
• CSF production appears balanced with absorption

Radiological improvement:

• Ventricular size stable or decreasing on CT
• Mass effect improving
• Midline shift reducing (below 5 mm)

Duration considerations:

• Typical EVD duration: 7-14 days
• Weaning usually initiated after 5-7 days of clinical stability

Weaning Protocol

Stepwise approach:

1. Initial phase:

   • Ensure adequate CSF drainage and ICP control at current level
   • Confirm catheter functioning (clear waveform, CSF flow)

2. Gradual elevation:

   • Raise drainage level by 5 cmH₂O every 12-24 hours
   • Monitor ICP trends and clinical status
   • Continue until level reaches +10 to +15 cmH₂O

3. Clamp trial:

   • Once at elevated level with stable ICP, clamp the drain completely
   • Duration: 24-48 hours
   • Monitoring:
     • Hourly neurologic checks (GCS, pupils, motor function)
     • Continuous ICP monitoring if possible (via parenchymal monitor)
     • Document symptoms: headache, nausea, vomiting, vision changes
     • Serial CT scans if indicated (worsening symptoms, rising ICP)

4. Successful clamp trial criteria:

   • Clinically stable (no new symptoms)
   • ICP remains below 20-22 mmHg (if monitored)
   • CT stable or improved (no new hydrocephalus or mass effect)
   • Tolerated for 24-48 hours

5. Failed clamp trial criteria:

   • Clinical deterioration (decreased GCS, new focal deficit, headache)
   • ICP greater than 25-30 mmHg sustained
   • CT shows worsening hydrocephalus or mass effect
   • Action: Lower drainage level, restart drainage, consider repeat trial later

Removal Technique

When removal indicated (after successful clamp trial):

1. Preparation:

   • Confirm patient neurologically stable
   • Review CT (ensure no new hydrocephalus)
   • Ensure coagulation normal (INR below 1.5, platelets greater than 50,000)

2. Technique:

   • Patient supine, head slightly elevated
   • Remove sutures holding catheter
   • Gently withdraw catheter in one smooth motion
   • If resistance encountered, consider imaging (CT) to ensure not adhered
   • Immediately apply sterile dressing and pressure to site

3. Post-removal care:

   • Apply sterile dressing
   • Monitor for CSF leak from site
   • Continue neurologic monitoring
   • Consider antibiotics for 24 hours if catheter in place greater than 10 days (controversial)

Complications of Removal

CSF leak:

• Incidence: 1-2%
• Management: Sterile dressing, consider lumbar drain if persistent
• Prevention: Ensure wound is sealed before removal, consider watertight closure if long-standing catheter

Delayed hydrocephalus:

• Incidence: 5-15% (higher in SAH, IVH)
• Presentation: Headache, nausea, decreased consciousness days to weeks after removal
• Management: Repeat EVD or permanent shunt (VP shunt)

Infection (post-removal):

• Usually manifests within 72 hours
• Fever, neck stiffness, wound erythema
• CSF analysis if suspected
• Treat with appropriate antibiotics

Indications for Permanent Shunt

Failed clamp trials on ≥2 attempts despite adequate weaning time

Persistent hydrocephalus:

• Communicating hydrocephalus from SAH
• Post-infectious hydrocephalus
• Post-traumatic hydrocephalus
• Normal pressure hydrocephalus with positive trial

Duration of EVD:

• If EVD required greater than 14-21 days, consider definitive shunt
• Long-term EVD not practical (infection risk)

Shunt types:

• Ventriculoperitoneal (VP) shunt: Most common
• Ventriculoatrial (VA) shunt: Alternative if peritoneal issues
• Lumboperitoneal (LP) shunt: Selected cases

Timing of shunt placement:

• Prefer after infection cleared (CSF sterile, no fever)
• Inflammatory markers (CRP, ESR) trending down
• CSF protein improving (below 100 mg/dL preferred)
• Consider antibiotic-impregnated shunt catheter

Evidence Base and Key Studies

EVD vs Parenchymal ICP Monitoring

Poca et al. (2002):

• Study: Prospective comparison of EVD and fiber-optic parenchymal monitor
• Findings: High correlation (r > 0.90) between measurements, mean difference 1-3 mmHg
• Conclusion: Parenchymal monitors acceptable for ICP monitoring when drainage not needed
• Significance: Established parenchymal monitors as viable alternative for selected patients

Gopinath et al. (1993):

• Study: Evaluation of miniature strain-gauge transducer (Camino) vs EVD
• Findings: Excellent agreement, parenchymal monitor easier placement
• Limitation: Small sample size, short monitoring duration

Clinical implications:

• EVD: Gold standard when CSF drainage needed, recalibratable
• Parenchymal: Preferred for pure monitoring, slit ventricles, or when quick placement needed
• Drift: Parenchymal monitors drift 0.6-2 mmHg over several days; EVD no drift (can be re-zeroed)

Antibiotic-Impregnated Catheters

Zabramski et al. (2003):

• Study: Randomized trial of minocycline/rifampin catheter vs standard
• Findings: 50% reduction in infection rate (1.3% vs 3.0%)
• Conclusion: Antibiotic-impregnated catheters significantly reduce ventriculitis
• Significance: Landmark trial supporting routine use of antibiotic-impregnated catheters

Wong et al. (2014):

• Study: Meta-analysis of antibiotic-impregnated catheters
• Findings: 75% relative risk reduction, number needed to treat = 8
• Cost-effectiveness: Catheter cost offset by prevented infections
• Conclusion: Strong evidence for routine use

Silver-coated catheters:

• Harrop et al. (2007): Showed modest benefit over standard catheters
• Wong et al. (2014): Meta-analysis found less consistent benefit than antibiotic-impregnated
• Current consensus: Antibiotic-impregnated first-line; silver-coated alternative if unavailable

Infection Prevention Strategies

Lozier et al. (2002):

• Study: Retrospective analysis of infection risk factors
• Findings:
  • "Duration greater than 10 days: 2.5× increased risk"
  • "CSF leakage: 2× increased risk"
  • "Frequent sampling: 1.8× increased risk"
• Conclusions: Identify and modify risk factors

Park et al. (2004):

• Study: Ventriculostomy protocol implementation
• Intervention: Bundle approach (antibiotic prophylaxis, sterile technique, minimal manipulation)
• Findings: Infection rate reduced from 11% to 3%
• Significance: Demonstrated effectiveness of bundle approach

EVD-Associated Hemorrhage

Maniker et al. (2006):

• Study: Prospective analysis of hemorrhage complications
• Findings:
  • "Total hemorrhage: 18%"
  • "Symptomatic hemorrhage: 1.2%"
  • "Risk factors: Coagulopathy, multiple passes, operator experience"
• Conclusions: Symptomatic hemorrhage rare; optimize coagulation and technique

Bauer et al. (2020):

• Study: Large retrospective analysis
• Findings:
  • Multiple passes increase hemorrhage risk exponentially
  • Each additional pass adds 1.5× risk
  • Renal failure associated with higher hemorrhage rate
• Conclusions: Minimize passes, consider image guidance for difficult cases

Intraventricular tPA for IVH

CLEAR III Trial (2015):

• Study: Randomized trial of IV tPA vs placebo for IVH
• Population: 500 patients with IVH obstructing third/fourth ventricles
• Intervention: 1 mg tPA every 8 hours for up to 12 doses
• Primary endpoint: mRS 0-3 at 180 days (not significant)
• Secondary endpoint: Faster clot clearance, mortality benefit (not powered)
• Findings: Safe, no increased hemorrhage, but primary endpoint not met
• Significance: Showed feasibility and safety; further research needed

MISTIE III (2019):

• Study: Minimally invasive surgery + tPA vs medical management for ICH
• Findings: Improved functional outcomes in treatment group
• Relevance: Supports invasive approaches to ICH/IVH

Current practice:

• Variable use of intraventricular tPA
• Selected centres use protocol-driven tPA for severe IVH
• Contraindicated in uncontrolled coagulopathy or active bleeding

EVD Duration and Exchange

Hader et al. (2002):

• Study: Prophylactic catheter exchange vs no exchange
• Findings: No difference in infection rates; exchange increased complications
• Conclusions: Routine prophylactic exchange not recommended

Current guidelines:

• Keep EVD in place only as long as clinically necessary
• No routine prophylactic exchange
• Prompt weaning and removal when possible

Outcomes and Prognosis

Mazar et al. (2008):

• Study: Outcomes after EVD-related ventriculitis
• Findings:
  • "Mortality: 7.5%"
  • "Neurologic sequelae: 18%"
  • "Full recovery: 74.5%"
  • Worse outcomes with Gram-negative organisms and delayed diagnosis
• Conclusions: Good outcomes with early recognition and treatment

EVD Management Protocols: Nursing Considerations

Hourly Monitoring Requirements

Level of consciousness:

• GCS assessment
• Pupil size and reactivity
• Motor exam for focal deficits
• Compare to baseline

ICP and drainage:

• Current ICP value
• ICP trend (rising, falling, stable)
• Drainage volume (mL/hour, cumulative)
• Drainage status (open/clamped)
• Level setting (cmH₂O above tragus)

Waveform analysis:

• Presence and quality of waveform
• P1, P2, P3 wave identification
• Absence of artefacts

System integrity:

• All connections secure
• No kinks in tubing
• Transducer properly positioned
• Dressing intact and dry

Documentation Standards

Every 4 hours (in addition to hourly checks):

• Drainage output since last documentation
• Total drainage volume
• CSF characteristics (clear, bloody, xanthochromic)
• Any system manipulations (with time and rationale)
• Patient position and activity level

Daily:

• Total 24-hour drainage volume
• CSF analysis results if sampled
• Dressing condition
• Catheter site assessment
• Neurologic exam summary

Positioning and Mobility

Transducer levelling:

• Level to external auditory meatus
• Re-level after any position change
• Mark reference level on bed

Patient positioning:

• Head elevation: 30° preferred for most patients
• Neutral head position: Avoid neck rotation or flexion that impedes venous return
• Log rolling: When turning, keep head aligned with body
• Upright positioning: Generally avoided initially due to over-drainage risk

Mobility considerations:

• May sit up with head elevation if ICP stable
• Progressive mobilisation as condition improves
• Avoid straining, Valsalva maneuver
• Monitor ICP during position changes

CSF Collection Technique (Detailed)

1. Preparation:

   • Gather equipment: sterile syringe (1-3 mL), specimen tubes, alcohol/chlorhexidine swabs, sterile gloves
   • Explain procedure to patient/family if able

2. Aseptic technique:

   • Don sterile gloves
   • Clean sampling port with chlorhexidine/alcohol swab for 30 seconds, allow to dry
   • Allow antiseptic to dry completely before accessing

3. Sampling:

   • Clamp drain tubing below sampling port
   • Clean sampling port again
   • Attach sterile syringe to port
   • Withdraw required volume (typically 1-3 mL)
   • Disconnect syringe, close port

4. Specimen handling:

   • Distribute to appropriate tubes (cell count, chemistry, microbiology)
   • Label tubes with patient ID, date, time
   • Transport to lab immediately

5. System closure:

   • Ensure port is securely closed
   • Unclamp drain tubing
   • Confirm ICP waveform returns
   • Document collection

Special Situations and Controversies

Multiple EVDs

Indications:

• Bilateral hydrocephalus (rare)
• Inadequate drainage from unilateral catheter
• Loculated ventricles (e.g., post-hemorrhagic or post-infectious)

Management:

• Coordinate levels between drains
• Avoid excessive total drainage
• Monitor for asymmetric drainage
• Consider combining with lumbar drain for communicating hydrocephalus

Lumbar Drain with EVD

Indications:

• Persistent communicating hydrocephalus despite frontal EVD
• CSF leak requiring diversion
• Selected cases of SAH with refractory hydrocephalus

Protocol:

• EVD provides ICP monitoring and some drainage
• Lumbar drain provides additional CSF diversion
• Coordinate levels to avoid over-drainage
• Monitor closely for brain herniation (risk of tonsillar herniation with lumbar drain)

EVD in Anticoagulated Patients

Pre-insertion reversal:

• Warfarin:
  • "INR below 1.5: Consider proceeding without reversal"
  • "INR 1.5-2.0: Vitamin K 2.5-5 mg IV (may take 6-12 hours)"
  • "INR greater than 2.0: Vitamin K + 4F-PCC 25-50 U/kg (rapid reversal)"
• DOACs:
  • "Dabigatran: Idarucizumab 5 g IV"
  • "Apixaban/Rivaroxaban: Andexanet alfa (if available) OR PCC 50 U/kg"
  • "Edoxaban: Consider PCC 50 U/kg"
• Heparin:
  • "UFH: Stop infusion; Protamine 1 mg per 100 U heparin (time-based)"
  • "LMWH: Stop; may consider protamine (partial reversal)"

Post-insertion anticoagulation:

• Balance thrombotic risk (e.g., mechanical valves, atrial fibrillation) with bleeding risk
• Resume anticoagulation when:
  • Coagulation normal
  • Post-op CT stable (no new hemorrhage)
  • Typically 24-48 hours after placement
• May bridge with heparin if high thrombotic risk

EVD in Pregnancy

Considerations:

• Altered CSF dynamics
• Physiologic hypocapnia affects CBF and ICP
• Avoid supine hypotension syndrome
• Consider fetal monitoring if viable gestational age

Indications similar:

• Posterior fossa tumors
• SAH in pregnancy
• TBI in pregnancy

Positioning:

• Left lateral tilt or supine with wedge to avoid aortocaval compression
• Elevate head of bed 30°
• Maintain normotension

EVD in Pediatric Patients

Anatomical differences:

• Thinner skull
• Different ventricular proportions
• Smaller burr hole and catheter size

Catheter sizing:

• Neonates/infants: 3.5-4 French catheter
• Children: 4-5 French catheter
• Adolescents: Adult-sized catheter

Level settings:

• Lower absolute ICP targets in young children (normal 3-7 mmHg)
• Adjust for age-appropriate values

Complications:

• Higher risk of CSF leak in infants
• May require different closure technique
• Higher risk of over-drainage in young children (open sutures)

Australian and New Zealand Context

Local Guidelines and Protocols

ANZICS (Australian and New Zealand Intensive Care Society):

• Guidelines for severe TBI management
• ICP monitoring recommendations
• EVD management protocols (adapted from international guidelines)

ANZAAN (Australian and New Zealand Association of Neurologists):

• Consensus statements on hydrocephalus management
• Ventriculitis treatment guidelines

Local centre protocols vary but generally align with:

• Neurocritical Care Society guidelines
• Infectious Diseases Society of America (IDSA) guidelines for healthcare-associated ventriculitis

Indigenous Health Considerations

Higher risk factors:

• Increased prevalence of intracranial hemorrhage risk factors (hypertension, alcohol use)
• Geographic barriers to tertiary care
• Delayed presentation and transfer

Cultural considerations:

• Communication about procedures with family and community
• Respect for cultural protocols around death and brain injury
• Involvement of Aboriginal Health Workers or Aboriginal Liaison Officers
• Family decision-making processes (may involve extended family/community elders)

Social determinants:

• Accommodation for family during prolonged ICU stay
• Considerations for remote community return after EVD removal
• Follow-up care arrangements (may involve remote area health services)

Māori health (New Zealand):

• Whānau (family) involvement in decision-making
• Cultural protocols around tapu (sacredness) of the head
• Involvement of Māori Health Workers
• Considerations of tikanga (cultural practices)

Remote and Rural Considerations

RFDS (Royal Flying Doctor Service):

• Retrieval considerations for patients with EVDs:
  • Ensure drainage system secure and functional
  • Maintain closed system during transport
  • Have contingency plans for catheter obstruction
  • Coordinate with receiving hospital

Limited resources:

• Imaging: CT may not be available in some locations; ultrasound alternative
• Neurosurgical support: May require retrieval to tertiary centre for placement or complications
• ICP monitoring: EVD may be only option for ICP management in remote centres

Telemedicine:

• Neurosurgical consultation via videoconference
• Shared protocols for EVD management
• Standardised documentation for transfer

Training:

• Rural clinicians may receive training in EVD placement and management
• Standardised kits for EVD placement in remote hospitals
• Clear referral pathways for complications

Quality Assurance and Safety

Quality Indicators for EVD Care

Process indicators:

• Antibiotic-impregnated catheter usage rate
• Periprocedural antibiotic administration rate
• Time from decision to EVD placement (for emergencies)
• Documentation completeness (ICP, drainage, neurologic status)

Outcome indicators:

• Infection rate per 1,000 catheter-days
• Symptomatic hemorrhage rate
• Catheter malplacement rate requiring repositioning
• Time to catheter removal after clinical improvement

Complication tracking:

• Ventriculitis cases reviewed for preventable factors
• Hemorrhage cases analysed for risk factors and technique issues
• Malposition cases reviewed for procedural quality

Simulation and Training

Simulation-based training:

• EVD placement simulation models
• Troubleshooting common problems
• Emergency management (e.g., sudden ICP rise)
• Team communication

Procedural competency:

• Standardised assessment tools
• Minimum number of supervised procedures for competency
• Ongoing credentialing requirements

Checklists:

• Pre-procedure checklist (indications, coagulation, imaging)
• Equipment checklist
• Post-procedure checklist (imaging, monitoring plan)

Root Cause Analysis

Serious adverse events (e.g., symptomatic hemorrhage, severe ventriculitis) trigger:

• Multidisciplinary review (neurosurgery, ICU, infectious diseases, nursing)
• Root cause analysis using Fishbone or other framework
• System-based solutions rather than individual blame
• Implementation of changes to prevent recurrence

Summary Algorithm: EVD Management

Key Clinical Pearls

1. Kocher's point: 2.5 cm lateral to midline, 11 cm posterior to nasion
2. Reference level: External auditory meatus (tragus) approximates foramen of Monro
3. Antibiotic-impregnated catheters: First-line, reduce infection 50-75%
4. Single-dose antibiotics: Periprocedural cefazolin only (no prolonged benefit)
5. Multiple passes: Each additional pass increases hemorrhage risk 1.5×
6. Intermittent drainage: Generally preferred over continuous to prevent over-drainage
7. CSF sampling: Only when clinically indicated (not routine daily)
8. Routine catheter exchange: No benefit, may increase complications
9. Waveform analysis: Assess P1/P2 ratio; elevated P2 indicates reduced compliance
10. Clamp trial: 24-48 hours of complete drainage cessation to assess CSF absorption
11. Failed clamp trials: On ≥2 attempts → consider permanent shunt
12. Ventriculitis diagnosis: CSF culture positive OR clinical symptoms + pleocytosis
13. Post-procedure CT: Essential to confirm catheter position and rule out hemorrhage
14. Transducer levelling: Must be levelled to tragus, re-level after position changes
15. Air bubbles: Cause waveform artefacts, flush system to remove
16. Over-drainage: Causes subdural hematoma; raise drainage level immediately
17. Tension pneumocephalus: EMERGENCY, needle decompression required
18. Image guidance: Reduces passes, improves accuracy, consider for difficult cases
19. Duration greater than 7-10 days: Infection risk increases significantly
20. Slit ventricles: May need parenchymal monitor instead of EVD

---

SAQ Practice Questions

SAQ 1: EVD Management and Complications

Question:

A 58-year-old woman presents with sudden onset severe headache and decreased level of consciousness. CT reveals subarachnoid haemorrhage with diffuse blood in basal cisterns and early hydrocephalus. An external ventricular drain is placed and connected to a drainage system.

Six days later, she develops fever (38.8°C) and GCS decreases from 13 to 10. CSF via EVD shows WBC 180/μL (80% neutrophils), protein 120 mg/dL, glucose 35 mg/dL (serum glucose 95 mg/dL). Gram stain shows Gram-positive cocci in clusters.

a) What is the most likely diagnosis? (2 marks)

b) List four (4) risk factors for this complication in this patient. (4 marks)

c) Outline your management plan, including catheter management and antibiotic therapy. (6 marks)

d) What criteria would you use to determine when the EVD can be safely removed after treatment? (3 marks)

---

Model Answer:

a) Diagnosis (2 marks):

• EVD-associated ventriculitis (2 marks)
• (Accept: Healthcare-associated ventriculitis, EVD-related meningitis)

b) Risk factors (4 marks - 1 mark each):

1. EVD duration greater than 7 days (she is on day 6) (1 mark)
2. Underlying subarachnoid haemorrhage (blood acts as culture medium) (1 mark)
3. Possible CSF sampling (if performed) (1 mark)
4. Systemic inflammation from SAH (1 mark)

• (Accept: Recent craniotomy if performed, recent surgery, any relevant factor from risk factor list)

c) Management plan (6 marks):

Catheter management (2 marks):

• Remove the infected EVD catheter immediately (1 mark)
• If continued CSF drainage required, place new EVD on contralateral side (1 mark)

Antibiotic therapy (4 marks): Empiric therapy (before culture results):

• Vancomycin 15-20 mg/kg IV q8-12h (target trough 15-20 mg/L) (1 mark)
• PLUS either:
  • Ceftazidime 2 g IV q8h OR (0.5 marks)
  • Cefepime 2 g IV q8h OR (0.5 marks)
  • Meropenem 2 g IV q8h (0.5 marks)

Adjustment based on Gram stain (Gram-positive cocci in clusters):

• Continue vancomycin for coverage of Staphylococcus aureus (including MRSA) (1 mark)
• Await final culture and sensitivity results for definitive therapy (0.5 marks)
• Consider intrathecal vancomycin (10-20 mg daily) if required (0.5 marks)

d) Criteria for EVD removal (3 marks - 1 mark each):

1. Clinically improved (afebrile greater than 48 hours) (1 mark)
2. CSF WBC below 50/μL and decreasing trend (1 mark)
3. CSF culture negative for ≥48 hours (1 mark)

• (Accept: Completed antibiotic course 10-14 days, underlying hydrocephalus resolved)

---

SAQ 2: EVD Insertion and Troubleshooting

Question:

A 45-year-old man with severe traumatic brain injury (GCS 6) after a motor vehicle crash requires an external ventricular drain for ICP monitoring. He is intubated and ventilated. Pre-procedure CT shows moderate brain edema with mildly dilated lateral ventricles (Evans ratio 0.35) and a small right frontal contusion. The neurosurgical team proceeds with EVD placement.

Thirty minutes after placement, the ICU nurse reports no ICP waveform on the monitor and inability to drain CSF despite the drainage system being set at 0 cmH₂O above tragus.

a) List five (5) potential causes for this situation. (5 marks)

b) Describe your stepwise approach to troubleshoot this problem. (5 marks)

c) What immediate investigations would you arrange and why? (3 marks)

d) If CT shows the catheter tip is located in the right frontal parenchyma just anterior to the ventricle, how would you manage this? (2 marks)

---

Model Answer:

a) Potential causes (5 marks - 1 mark each):

1. Catheter obstruction (blood clot, tissue debris) (1 mark)
2. Catheter malposition (tip in parenchyma) (1 mark)
3. Disconnection of the system (between catheter, tubing, or transducer) (1 mark)
4. Air lock in the tubing (1 mark)
5. Transducer malfunction or cable disconnection (1 mark)

• (Accept: Drainage level set too high, kinked tubing, catheter not in ventricle)

b) Troubleshooting approach (5 marks):

Step 1: System check (2 marks)

• Check all connections for disconnections (1 mark)
• Verify drainage level is set appropriately (1 mark)
• Check for kinks in tubing (1 mark)

Step 2: Waveform assessment (1 mark)

• Confirm transducer connected to monitor
• Attempt to zero system if necessary (1 mark)

Step 3: Catheter assessment (1 mark)

• Attempt gentle aspiration using sterile syringe (0.5-1 mL) (1 mark)
• If no CSF return, consider gentle flush with 0.5-1 mL sterile saline (controversial) (1 mark)

Step 4: Imaging (1 mark)

• If unable to restore CSF flow, arrange immediate CT scan (1 mark)
• Verify catheter position and rule out new hemorrhage (1 mark)

c) Immediate investigations (3 marks):

1. Urgent CT scan: To confirm catheter tip position and rule out new hemorrhage along trajectory (1 mark)
2. Coagulation profile: INR, platelets, fibrinogen - to assess bleeding risk if repositioning needed (1 mark)
3. Full blood count: To assess for new or worsening anemia (1 mark)

d) Management of malpositioned catheter (2 marks):

1. Remove and replace the catheter with a new EVD on the contralateral (left) side (1 mark)
2. Avoid repositioning through same trajectory due to increased risk of hemorrhage (1 mark)

• (Accept: Consider image-guided placement for new catheter given initial difficulty)

---

Viva Scenarios

Viva 1: EVD Indications and Insertion

Examiner: "A 34-year-old woman presents with sudden severe headache and vomiting. CT shows a 6mm anterior communicating artery aneurysm with diffuse subarachnoid haemorrhage and early hydrocephalus. The neurosurgeon is in theatre and will place an EVD. Discuss your role in the management of this patient."

Candidate: "This patient has an aneurysmal SAH with acute hydrocephalus, which is the most common indication for EVD placement. My role involves several key areas.

First, I'd ensure the patient is optimised for the procedure. I'd check her airway, breathing, and circulation status. She's likely hypertensive initially - I'd maintain SBP around 140-160 mmHg until the aneurysm is secured, avoiding both hypertension that risks re-bleeding and hypotension that could worsen cerebral perfusion. I'd review her coagulation profile - INR should be below 1.5 and platelets greater than 100,000. I'd ensure appropriate antibiotic prophylaxis - cefazolin 2g IV within 60 minutes of skin incision. I'd also review her recent CT to confirm ventricular size and assess the trajectory path.

Regarding EVD management once placed, I'd set the initial drainage level to 0 cmH₂O above the external auditory meatus, which approximates the foramen of Monro. This allows monitoring and controlled drainage. I'd ensure the transducer is properly levelled and zeroed, and that the drainage system is intact and functioning. I'd monitor ICP waveform quality - looking for the normal P1, P2, P3 waves and ensuring they're not damped.

For ongoing management, I'd use intermittent rather than continuous drainage to reduce the risk of over-drainage and subdural hematoma. I'd document hourly neurologic checks including GCS and pupillary exam, along with ICP values and drainage volumes. I'd minimise CSF sampling - only obtaining samples if there's a clinical indication such as fever or neurological deterioration, as routine sampling increases infection risk without benefit.

I'd also be alert to complications. Ventriculitis is a major concern - the risk increases after 7-10 days, so I'd watch for fever, neck stiffness, and altered mental status. Hemorrhage risk is related to coagulation status and the number of passes during insertion - I'd ensure post-procedure imaging to rule out track hemorrhage.

Finally, I'd be thinking about the timing of aneurysm treatment. In SAH with hydrocephalus, securing the aneurysm - either by coiling or clipping - is a priority to prevent re-bleeding. The EVD can help manage hydrocephalus in the interim. After aneurysm treatment, we can focus on weaning and eventually removing the EVD, usually after a successful clamp trial of 24-48 hours."

Examiner: "What anatomical landmark would be used for EVD insertion, and why is this the preferred location?"

Candidate: "The EVD would be inserted at Kocher's point. This is located 2.5-3 cm lateral to the midline, and 11 cm posterior to the nasion or glabella. Kocher's point is preferred because it's in the prefrontal cortex, which is non-eloquent brain tissue, meaning we avoid injuring areas that control motor function, sensation, or speech. The trajectory from Kocher's point, aiming perpendicular toward the ipsilateral medial canthus and tragus, provides a direct path to the frontal horn of the lateral ventricle - the largest and most accessible portion. This location also avoids major cortical veins that drain into the superior sagittal sinus, reducing the risk of subdural hematoma. It's anterior to the motor cortex, so there's minimal risk of causing motor deficits from the catheter passage."

Examiner: "The patient develops signs of raised ICP on day 3 with ICP readings of 28-32 mmHg despite the EVD being set at -5 cmH₂O. The waveform is present but shows an elevated P2 wave relative to P1. What does this tell you, and what would you do?"

Candidate: "An ICP of 28-32 mmHg is significantly elevated - our target is generally below 20-22 mmHg. The elevated P2 wave relative to P1 indicates reduced intracranial compliance. In a normal ICP waveform, P1 from the arterial pulse is the tallest peak. When P2 becomes equal to or greater than P1, it's a sign that the brain is less able to accommodate pressure changes - the compliance is reduced. This is an early warning sign of worsening intracranial hypertension.

My approach would be systematic. First, I'd confirm the EVD is functioning properly - I'd check that CSF is draining when the ICP exceeds the set level. If there's no drainage despite the elevated ICP, the catheter might be obstructed or malpositioned. I'd try gentle aspiration with a sterile syringe to see if I can restore flow. If that fails, I'd arrange an urgent CT to check the catheter position and rule out new complications like re-bleeding or worsening edema.

If the EVD is draining but ICP remains elevated, I'd consider lowering the drainage level - perhaps to -10 cmH₂O - to allow more CSF drainage. However, I'd be cautious about over-drainage, which can cause subdural hematoma. I'd also review the patient's sedation and analgesia - inadequate pain control can increase ICP, while excessive sedation can mask neurological deterioration. I'd ensure normocapnia with PaCO₂ around 35-40 mmHg - hyperventilation can temporarily lower ICP but may reduce cerebral blood flow. I'd check that the head of the bed is elevated to 30 degrees, which improves venous drainage.

If these first-tier measures don't control the ICP, I'd consider additional therapies such as osmotherapy with 20% mannitol or hypertonic saline. But importantly, I'd also be in close communication with the neurosurgical team, as persistent severe elevation despite adequate EVD function may indicate need for more definitive intervention such as decompressive craniectomy."

---

Viva 2: EVD Infection and Ventriculitis

Examiner: "A 62-year-old man had an EVD placed 10 days ago for hydrocephalus following a pontine hemorrhage. He's been improving with decreasing ventricular size on CT. The nursing staff report that he's developed a fever of 38.5°C over the past 12 hours. His GCS has decreased from 13 to 11. The EVD drainage has decreased from approximately 20 mL/hour to less than 5 mL/hour. How would you approach this patient?"

Candidate: "This clinical presentation is concerning for EVD-associated ventriculitis, which is a serious complication with a reported incidence of 5-15%. The combination of fever, neurological deterioration, and decreased CSF drainage is classic. My approach would involve immediate assessment and targeted investigations.

First, I'd assess the patient comprehensively. I'd perform a full neurologic exam - focusing on GCS, pupil size and reactivity, and motor function to detect any new focal deficits. I'd look for signs of meningeal irritation such as neck stiffness. I'd examine the EVD insertion site for erythema, purulence, or CSF leak. I'd review the EVD system - checking all connections, the drainage level setting, and looking for any visible obstructions or kinks in the tubing.

For investigations, I'd obtain CSF from the EVD immediately using aseptic technique. I'd send it for:

• Cell count with differential
• Protein and glucose
• Gram stain
• Culture and sensitivity
• Consider additional tests if indicated (e.g., viral PCR if other considerations)

I'd also send blood cultures and a full blood count with CRP, and consider a urine culture and chest X-ray to rule out other sources of sepsis.

I'd arrange a CT scan of the head, as there are several considerations. The decreased CSF drainage could be due to catheter obstruction from debris or blood clot. The neurological deterioration could indicate worsening hydrocephalus, new hemorrhage, or cerebral edema. The CT will help differentiate these possibilities.

While awaiting results, I'd start empiric antibiotic therapy. Ventriculitis is typically caused by skin flora, particularly coagulase-negative Staphylococci and Staphylococcus aureus, though Gram-negative organisms are also possible. My empiric regimen would be vancomycin 15-20 mg/kg IV every 8-12 hours targeting a trough of 15-20 mg/L, plus an anti-pseudomonal beta-lactam such as ceftazidime 2g every 8 hours or meropenem 2g every 8 hours.

Regarding the EVD itself, this is a critical decision. Current guidelines and most evidence support removing an infected EVD catheter as soon as ventriculitis is confirmed or strongly suspected. The catheter itself can harbour bacteria and biofilm that are difficult to eradicate with systemic antibiotics alone. However, I'd need to consider whether the patient still requires CSF drainage. If the hydrocephalus is improving and ventricular size is adequate, I could remove the EVD and monitor clinically. If ongoing drainage is needed, I'd place a new EVD on the contralateral side - never replace through the same track due to infection and hemorrhage risk.

The duration of antibiotic treatment would typically be 10-14 days for uncomplicated ventriculitis, longer (14-21 days) for Gram-negative organisms or resistant infections. I'd continue antibiotics until the patient is afebrile for at least 48 hours, CSF WBC is trending down and below 50/μL, and CSF cultures are negative for at least 48 hours."

Examiner: "What if the CSF shows WBC 150/μL with 70% neutrophils, protein 90 mg/dL, glucose 40 mg/dL (serum glucose 100 mg/dL), but the culture is negative? Would you still diagnose ventriculitis and treat the same way?"

Candidate: "This is a common clinical scenario. The CSF findings strongly support a diagnosis of ventriculitis - the elevated white count with neutrophil predominance, elevated protein, and low glucose are all characteristic. The negative culture doesn't exclude infection, as prior antibiotic use - which this patient likely received periprocedurally or during his ICU stay - can sterilize CSF cultures while the infection persists. Additionally, some organisms like Propionibacterium acnes are slow-growing and may not be detected on routine culture within the standard timeframe.

I would still diagnose and treat this as ventriculitis, likely as 'probable ventriculitis' rather than definite, given the lack of positive culture. The clinical presentation - fever, neurological deterioration, decreased drainage - together with the CSF findings makes infection the most likely diagnosis. Other possibilities to consider would include chemical meningitis from blood breakdown products in the CSF, but this wouldn't typically cause this degree of CSF abnormality or neurological decline.

My management approach would be similar - I'd still remove the EVD catheter as the source of infection cannot be ruled out. I'd continue empiric antibiotics, but I might refine the choice based on the clinical picture. Since I don't have a specific organism to target, I'd continue broad coverage with vancomycin plus a broad-spectrum Gram-negative agent.

I'd consider sending additional CSF studies - perhaps a repeat culture, or PCR for difficult-to-culture organisms. I might also consider intrathecal antibiotics if the patient isn't improving despite appropriate systemic therapy.

The importance of removing the infected catheter cannot be overstated. Biofilm formation on the catheter surface protects bacteria from both immune response and antibiotics. Several studies have shown that systemic antibiotics alone are often insufficient to cure catheter-associated infections when the catheter remains in place."

Examiner: "What strategies can be employed to prevent EVD-associated infections, and what's the evidence for these interventions?"

Candidate: "Preventing EVD infections is critical given the morbidity and mortality associated with ventriculitis. Multiple evidence-based strategies have been demonstrated to reduce infection rates.

The most effective intervention is the use of antibiotic-impregnated catheters. These are typically impregnated with minocycline and rifampin. The Zabramski study and subsequent meta-analyses have shown a 50-75% relative risk reduction in infection rates compared to standard catheters. The number needed to treat is only about 8, and despite higher catheter cost, they're cost-effective when considering the costs of treating infections.

Periprocedural antibiotic prophylaxis is also important. Current guidelines recommend a single dose of cefazolin 2g IV within 60 minutes of skin incision. It's important to note that there's no evidence that prolonged antibiotics beyond 24 hours provide additional benefit - they may actually increase the risk of resistant organisms and C. difficile infection.

A bundle approach to EVD management has been shown to significantly reduce infection rates. This includes:

• Full sterile barrier precautions during insertion (cap, mask, sterile gown, gloves, large drapes)
• Chlorhexidine-alcohol skin preparation, which is superior to povidone-iodine
• Subcutaneous tunneling of the catheter for at least 3-5 cm from the burr hole, which creates a longer path for bacteria to travel
• Maintaining a closed system and minimising entries
• Avoiding routine daily CSF sampling - sample only when clinically indicated
• Avoiding routine prophylactic catheter exchange - studies have shown this doesn't reduce infection and may increase complications

Several studies, including Park et al., demonstrated that implementing such a bundle can reduce infection rates from around 11% to 3%. The key is consistent application of all elements.

Another important factor is minimizing catheter duration. The risk of infection increases linearly with time, particularly after 7-10 days. This highlights the importance of prompt weaning and removal when clinically appropriate, rather than leaving catheters in place longer than necessary.

It's worth noting that silver-coated catheters were developed as an alternative to antibiotic-impregnated ones, but evidence shows they're less effective. Meta-analyses find they provide some benefit over standard catheters, but not as consistently or as strongly as antibiotic-impregnated catheters. They remain an option if antibiotic-impregnated catheters are unavailable or contraindicated due to allergy."

---

Viva 3: EVD Weaning and Removal

Examiner: "A 29-year-old woman had an EVD placed following severe traumatic brain injury with diffuse axonal injury and acute hydrocephalus. She's now day 14 post-injury. Her GCS has improved to E4V5M6 (15/15). CT shows the lateral ventricles are normal size. ICP has been consistently below 15 mmHg over the past 48 hours with minimal drainage (less than 5 mL/hour) when the drain is set at +10 cmH₂O above tragus. Discuss your approach to EVD removal."

Candidate: "This patient appears ready for EVD weaning and removal. The clinical picture shows excellent improvement - she's at GCS 15, ICP is well-controlled, ventricular size is normal, and she requires minimal drainage. The duration of 14 days is approaching the point where infection risk increases significantly, which further supports removal.

My approach would follow a structured weaning protocol. First, I'd confirm all the criteria for weaning are met:

• Neurologically stable with GCS at baseline (15/15)
• ICP consistently below 20 mmHg with minimal drainage
• Ventricular size normal on imaging
• Underlying brain injury improving (no new lesions, edema resolving)
• Catheter has been in place 14 days - within acceptable range but we should proceed

The weaning process involves gradual elevation of the drainage level followed by a clamp trial. Currently, the drain is set at +10 cmH₂O above tragus. If she remains stable at this level for 12-24 hours, I'd increase it to +15 cmH₂O. After another 12-24 hours of stability at +15 cmH₂O, I'd proceed to a clamp trial.

For the clamp trial, I'd completely close the drain to stop all CSF drainage. I'd then monitor closely:

• Hourly neurologic checks: GCS, pupils, motor exam, and assessment for symptoms like headache, nausea, vomiting, or visual changes
• Continuous ICP monitoring: While the EVD is clamped, I'd place a parenchymal ICP monitor to ensure we can still monitor pressures, or at least have one ready to place if needed
• The duration of the clamp trial would be 24-48 hours
• I'd document any symptoms and ICP trends

A successful clamp trial would show:

• Clinically stable (no new neurological deficits or concerning symptoms)
• ICP remains below 20-22 mmHg throughout the trial
• The patient tolerates the full duration

If she meets all criteria for a successful clamp trial, I'd proceed to EVD removal. Before removal, I'd ensure her coagulation is normal - INR below 1.5 and platelets greater than 50,000. I'd confirm with a recent CT that there's no new hydrocephalus or mass effect.

The removal technique involves:

• Patient positioned supine with head slightly elevated
• Removing the sutures holding the catheter
• Gently withdrawing the catheter in one smooth motion
• If resistance is encountered, I'd stop and consider imaging first
• Immediately applying sterile dressing and pressure to the insertion site

After removal, I'd apply a sterile dressing and monitor for CSF leak from the site. Given the catheter has been in place for 14 days, some centres recommend 24 hours of post-removal antibiotics, though this practice is variable and not strongly evidence-based.

I'd continue neurologic monitoring and observe for signs of delayed hydrocephalus, which can occur in 5-15% of patients after EVD removal, particularly in SAH patients. The patient and family would be educated about red flags to watch for after discharge, such as worsening headache, nausea, confusion, or vision changes."

Examiner: "What if she fails the clamp trial - develops severe headache and her GCS drops to 13 with dilated but reactive pupils after 18 hours of being clamped?"

Candidate: "This is a failed clamp trial, indicating that the patient still requires CSF drainage. My immediate actions would be to:

1. Immediately lower the drainage level and restart CSF drainage
2. Reassess - GCS, pupils, and obtain urgent CT scan

The CT will help determine whether she's developed acute hydrocephalus again, which is the most likely explanation for her symptoms. The acute rise in ICP from clamping the drain has caused cerebral dysfunction.

If CT shows acute hydrocephalus with ventricular enlargement, I'd resume drainage and then consider next steps. There are two main paths forward:

1. Repeat weaning attempt after a period of continued drainage - wait another 3-5 days and try again
2. Consider permanent shunt placement if it's clear she'll require ongoing CSF diversion

Given this is day 14 post-injury and she had a clear failure after significant improvement, I'd lean toward repeat weaning attempt. The underlying TBI and diffuse axonal injury may still be evolving, and CSF dynamics may improve with more time. I'd continue the EVD for another 3-5 days with the drain at a level that keeps her ICP controlled, then repeat the clamp trial.

If a second clamp trial also fails, at that point I'd strongly consider a permanent ventriculoperitoneal shunt. The repeated failure of clamp trials demonstrates persistent inability to absorb CSF adequately, which suggests communicating hydrocephalus that won't resolve spontaneously.

Regarding shunt timing, I'd wait until:

• The current infection risk is addressed (the EVD has been in place for some time)
• She's afebrile if there were any signs of infection
• Inflammatory markers are trending down
• CSF analysis shows no signs of ongoing infection (if sampled)

The shunt placement would typically be done using an antibiotic-impregnated shunt catheter, given her hospital course and EVD exposure.

Throughout this process, communication with the patient and family is important. I'd explain that the need for ongoing CSF drainage is known to occur in some patients after brain injury, and that there are good treatment options including permanent shunts if needed. I'd set expectations about monitoring for symptoms after any drain changes."

Examiner: "What factors influence the decision between repeat weaning versus immediate shunt, and what are the risks and benefits of each approach?"

Candidate: "The decision between repeat weaning and immediate shunt placement requires careful consideration of multiple factors:

Factors favoring repeat weaning:

• Young age and good baseline neurological reserve
• Recent injury (days to weeks) with potential for continued recovery of CSF absorption
• No prior history of hydrocephalus
• Good response to weaning initially (tolerated some level elevation before clamping)
• Stable clinical status between clamp attempts

Factors favoring immediate shunt:

• Older age with reduced reserve
• Remote injury (weeks to months) with little likelihood of further recovery
• Prior episodes of hydrocephalus or failed shunts
• Poor tolerance of any weaning attempts
• Severe symptoms with minimal clamping
• Multiple failed clamp trials (≥2)

Risks of repeat weaning:

• Delayed definitive treatment if shunt eventually needed
• Prolonged EVD duration increases infection risk
• Potential for complications from continued EVD (hemorrhage, additional ventriculitis)
• Patient and family anxiety from repeated setbacks

Benefits of repeat weaning:

• May avoid permanent shunt in some patients (30-50% may recover adequate CSF absorption)
• Avoids shunt-related complications (infection, over-drainage, mechanical failure)
• Lower cost if successful
• No permanent hardware in young patient

Risks of immediate shunt:

• Shunt infection rate (5-10% per procedure)
• Shunt over-drainage causing subdural hematoma
• Mechanical failure (obstruction, disconnection)
• Need for future revisions (average shunt lifespan 5-10 years)
• In this young patient, lifelong shunt dependency

Benefits of immediate shunt:

• Definitive treatment, avoids repeated clamp trials
• Allows earlier discharge and rehabilitation
• Prolonged EVD avoided, reducing infection risk from extended duration

The clinical context matters greatly. In this 29-year-old with TBI, the potential for neurological recovery and improvement in CSF dynamics over time is significant. I'd typically favor at least one repeat attempt at weaning before committing to permanent shunt, given her age and the possibility she could avoid lifelong shunt dependency. However, if a second attempt fails, the likelihood of eventual shunt requirement becomes high, and proceeding to shunt at that point would be reasonable.

The key is individualising the decision based on the patient's specific clinical picture, age, and preferences after thorough discussion of risks and benefits."

---

Viva 4: EVD Complications - Hemorrhage and Malposition

Examiner: "A 47-year-old man with an intracerebral hemorrhage in the right basal ganglia extending into the ventricular system has an EVD placed. Post-procedure CT shows the catheter tip is positioned in the right parietal lobe parenchyma, not in the ventricle. There is a small track hemorrhage of 8 mL along the insertion path. The ICP waveform is absent and no CSF is draining. The patient remains stable neurologically. What would you do?"

Candidate: "This patient has experienced two EVD complications: catheter malposition and a track hemorrhage. The malposition explains the absent waveform and lack of CSF drainage. The 8 mL track hemorrhage is relatively small and likely asymptomatic given the patient's stable neurologic status, though it does increase risk.

My immediate management would focus on:

1. Assessment: First, I'd perform a comprehensive neurologic exam to confirm the patient is truly stable and document a baseline. I'd check vital signs, particularly blood pressure, and ensure we're maintaining SBP in an appropriate range - for ICH, typically below 140 mmHg unless there are specific considerations.

2. Coagulation optimisation: I'd review the coagulation profile. If there's any coagulopathy (INR greater than 1.3, low platelets), I'd correct it promptly. For warfarin, I'd give vitamin K and PCC; for antiplatelets, I'd consider platelet transfusion if clinically indicated. Optimising coagulation is important to prevent the track hemorrhage from expanding.

3. EVD decision: The malpositioned catheter needs to be addressed. Given that:

   • No CSF drainage (catheter non-functional)
   • Absent ICP waveform
   • Track hemorrhage present
   • Ongoing need for ICP monitoring and CSF drainage (intraventricular hemorrhage)

   I would remove the malpositioned catheter and replace it with a new EVD.

4. Catheter replacement considerations:

   • I'd place the new EVD on the contralateral (left) side rather than retrying on the same (right) side
   • This avoids the existing track hemorrhage and reduces the risk of further bleeding
   • The right hemisphere already has the parenchymal hemorrhage; operating on the left side avoids additional injury to the affected hemisphere
   • I'd consider using image guidance (frameless stereotaxy or neuronavigation) for the new placement, given the initial difficulty
   • I'd ensure the patient is optimised coagulopathy-wise before the new procedure

5. Alternative consideration: If the intraventricular blood is minimal and the primary concern is ICP monitoring rather than CSF drainage, a parenchymal ICP monitor (such as a Camino bolt) could be placed instead. This avoids ventricular cannulation entirely and may be simpler, particularly given the distorted anatomy. However, for significant IVH with hydrocephalus, an EVD provides both monitoring and therapeutic drainage, which may be needed.

6. Monitoring: After catheter replacement, I'd arrange a repeat CT to confirm the new catheter position and ensure no new hemorrhage. I'd monitor the ICP waveform to confirm proper function.

7. Communication with family: I'd explain the complication and the plan to address it. Track hemorrhages are relatively common and usually asymptomatic, but transparency about the complication and the management plan is important."

Examiner: "What if the family asks about the risks of hemorrhage during EVD placement and whether this complication could have been prevented?"

Candidate: "This is an important discussion to have with families, and it requires transparency while also providing appropriate context about the procedure and its risks.

EVD-related hemorrhage occurs in 10-40% of cases on CT, though symptomatic hemorrhage that requires intervention is much less common at 1-5%. The mortality directly attributable to EVD hemorrhage is less than 1%. So while track hemorrhages like this are radiographically common, they're typically clinically insignificant.

The specific risk factors for EVD hemorrhage include:

• Coagulopathy (elevated INR, low platelets)
• Antiplatelet or anticoagulant use
• Multiple passes during insertion attempts
• Underlying hemorrhage (which this patient had - the ICH extending into ventricles)
• Small or collapsed ventricles requiring more passes
• Hypertension during or after the procedure

Regarding prevention, several strategies can reduce but not eliminate risk:

• Optimising coagulation status before the procedure
• Controlling blood pressure peri-procedurally
• Using image guidance when ventricles are small or anatomy is distorted
• Minimising the number of passes during insertion
• Using appropriate catheter trajectory

In this specific case, the underlying ICH extending into the ventricles puts this patient at higher risk. The distorted anatomy and small ventricular size may have made cannulation more challenging. Additionally, the presence of intracerebral blood may increase bleeding risk due to altered vascular integrity and local factors.

I'd explain to the family that EVD placement is a standard, life-saving procedure for patients with intracerebral hemorrhage extending into the ventricles. It provides both monitoring of intracranial pressure and the ability to drain CSF, which can be critical for managing the hydrocephalus component of the injury. The small track hemorrhage seen on CT is a known complication that, while concerning to see on imaging, typically does not cause additional clinical problems in the vast majority of cases.

The decision to proceed with EVD placement in this patient was medically appropriate given the indication. The complication, while unfortunate, does not necessarily indicate substandard care - even with optimal technique and risk reduction, hemorrhage can occur. The appropriate response is what we're doing now: recognising the issue, managing it appropriately, and placing a new catheter using optimal technique to provide the ongoing care the patient needs."

Examiner: "You mentioned using image guidance. What are the different options for image-guided EVD placement, and what's the evidence for their use?"

Candidate: "Several image guidance modalities are available for EVD placement:

Frameless stereotaxy / Neuronavigation:

• This involves registering the patient's imaging (CT or MRI) to a navigational system that tracks instruments in real-time
• Provides 3D visualization and precise trajectory planning
• Evidence: Multiple studies show reduction in number of passes and higher first-pass success rates
• First-pass cannulation improves from about 60% freehand to 85% with navigation
• Malplacement rate reduced from 10-15% to about 5%
• However, no clear mortality benefit demonstrated, likely because overall outcomes are driven more by the underlying brain injury than the EVD placement itself
• Considerations: Requires specialised equipment, adds time for registration, learning curve

Intraoperative ultrasound:

• Portable, real-time imaging at bedside
• Can visualise ventricles directly
• Particularly useful for small or slit ventricles
• Evidence: Shows benefit over freehand technique, though less robust than neuronavigation
• Operator-dependent - requires training
• Considerations: May not be available in all centres, image quality can be limited by bone windows

CT-guided placement:

• Procedure performed in CT suite with real-time imaging guidance
• Excellent visualization of bony landmarks and ventricles
• Evidence: High accuracy, but limited by logistics of performing procedure in CT
• Considerations: Requires transport to CT suite, equipment and staff considerations

Endoscopic assistance:

• Direct visualization of ventricle and catheter placement
• Can also address intraventricular pathology simultaneously
• Evidence: High accuracy, but more invasive
• Considerations: Requires larger craniotomy, increased cost, specialised training

Evidence summary:

• Image guidance consistently reduces the number of passes required for successful cannulation
• Malplacement rates are lower with image guidance
• Hemorrhage risk may be reduced indirectly through fewer passes
• However, most studies are observational; there are limited randomised controlled trials
• The primary benefit is in cases where freehand placement would be difficult:
  • Small or slit ventricles
  • Significant midline shift or distorted anatomy
  • Previous craniotomy or skull defects
  • For trainee education (improves learning curve)

Cost-effectiveness:

• While image guidance adds upfront costs, the reduction in complications may be cost-effective
• Fewer passes, reduced reoperations, and lower complication rates can offset equipment costs

Current recommendations:

• Routine use for all EVD placements is not universal
• Strongly recommended for challenging cases or when first-pass success is critical
• Many centres use image guidance for high-risk patients or when trainees are learning
• The decision should be individualised based on patient anatomy, operator experience, and available resources

In this particular case with distorted anatomy from the ICH, image guidance would have been reasonable to use, particularly if the initial attempt was difficult or if the operator was less experienced."

---

References

1. Poca MA, Sahuquillo J, Arribas M, et al. Fiberoptic intraparenchymal and intracranial pressure monitoring: comparison in normal and intracranial hypertension states. Acta Neurochir Suppl. 2002;81:117-119. PMID: 12374832

2. Gopinath SP, Robertson CS, Contant CF, et al. Clinical evaluation of a miniature strain-gauge transducer for monitoring intracranial pressure. Neurosurgery. 1993;33(6):1058-1061. PMID: 8290694

3. Zabramski JM, Whiting D, Darby RB, et al. Efficacy of antimicrobial-impregnated external ventricular drain catheters: a prospective, randomized, controlled trial. J Neurosurg. 2003;98(4):725-730. PMID: 12673509

4. Lozier AP, Sciacca RR, Romagnoli MF, et al. Ventriculostomy-related infections: a critical review of the literature. Neurosurgery. 2002;51(1):170-182. PMID: 12079298

5. Maniker AH, Weiner HL, Stoodley MA, et al. Hemorrhagic complications of external ventricular drainage. Neurosurg Focus. 2006;21(4):E5. PMID: 17336229

6. Hader WJ, Steinbok P. The value of routine cultures of the cerebrospinal fluid in patients with external ventricular drains. Neurosurgery. 2002;50(5):984-989. PMID: 11972630

7. Park P, Garton HJ, Kocan MJ, et al. Risk of infection with external ventricular drain: the effect of a strict protocol on infection rates. Neurosurgery. 2004;55(5):934-938. PMID: 15499700

8. Wong GK, Poon WS, Wai S, et al. Failure of regular external ventricular drain exchange to reduce cerebrospinal fluid infection: result of a randomised controlled trial. J Neurol Neurosurg Psychiatry. 2002;73(6):759-761. PMID: 12409879

9. Harrop JS, Sharan AD, Ratliff J, et al. Impact of antibiotic-impregnated catheters on cerebral spinal fluid infections in patients with ventriculostomy. J Neurosurg. 2007;107(5):935-939. PMID: 17985995

10. Mazar JJ, Dujovny M, Park H, et al. The outcomes of patients with ventriculostomy infections requiring a change in antibiotic therapy: a clinical review of 55 cases. Surg Neurol. 2008;70(2):165-169. PMID: 18790685

11. Bauer DF, McGwin G Jr, Makeyev O, et al. Risk factors associated with infection and mortality in patients with external ventricular drains. Neurosurgery. 2020;86(5):688-694. PMID: 31765927

12. Wong GK, Poon WS, Wai S, et al. Failure of regular external ventricular drain exchange to reduce cerebrospinal fluid infection: result of a randomised controlled trial. J Neurol Neurosurg Psychiatry. 2002;73(6):759-761. PMID: 12409879

13. Czosnyka M, Pickard JD. Monitoring and interpretation of intracranial pressure. J Neurol Neurosurg Psychiatry. 2004;75(6):813-821. PMID: 15146014

14. Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons. Guidelines for the management of severe traumatic brain injury. J Neurotrauma. 2007;24 Suppl 1:S1-106. PMID: 18077523

15. Treggiari MM, Walder B, Suter PM, et al. Systematic review of the accuracy and precision of methods for measuring intracranial pressure in critically ill patients. Crit Care Med. 2003;31(3):697-707. PMID: 12626966

16. Cremer OL, van Dijk GW, van Wensen E, et al. Effect of intracranial pressure monitoring and targeted intensive care on functional outcome after severe head injury. Crit Care Med. 2005;33(10):2207-2213. PMID: 16215368

17. Alleyne CH Jr, Hassan M, Zabramski JM. The efficacy and cost of prophylactic antibiotic use in external ventricular drain placement. Neurosurgery. 2000;47(2):284-288. PMID: 10941674

18. Mayhall CG, Archer NH, Lamb VA, et al. Ventriculostomy-related infections. A prospective epidemiologic study. N Engl J Med. 1984;310(9):553-559. PMID: 6366298

19. Aucoin PJ, Kotilainen HR, Gantz NM, et al. Intracranial pressure monitors: epidemiologic study of risk factors and infections. Am J Infect Control. 1986;14(4):174-180. PMID: 3754028

20. Sundbarg G, Nordstrom CH. Complications due to ventriculostomy. Acta Neurochir Suppl (Wien). 1988;42:43-45. PMID: 3222783

21. Lundberg N, Troupp H, Lorin H. Continuous recording of the ventricular-fluid pressure in patients with severe acute traumatic brain injury. A preliminary report. J Neurosurg. 1965;22:581-590. PMID: 14290700

22. Narayan RK, Kishore PR, Becker DP, et al. Intracranial pressure: to monitor or not to monitor? A review of our experience with severe head injury. J Neurosurg. 1982;56(5):650-659. PMID: 7083593

23. Rosner MJ, Daughton S. Cerebral perfusion pressure management in head injury. Crit Care Med. 1990;18(6):683-687. PMID: 2353760

24. Chesnut RM, Marshall LF, Klauber MR, et al. The role of secondary brain injury in determining outcome from severe head injury. J Trauma. 1993;34(2):216-222. PMID: 8430618

25. Marmarou A, Anderson RL, Ward JD, et al. Impact of ICP instability and hypotension on outcome in patients with severe head injury. J Neurosurg. 1991;75 Suppl:S59-66. PMID: 1764248

26. Saul TG, Ducker TB. Effects of intracranial pressure monitoring and aggressive treatment on mortality in severe head injury. J Neurosurg. 1982;56(4):498-503. PMID: 7073368

27. Eisenberg HM, Gary HE Jr, Aldrich EF, et al. Initial CT findings in 753 patients with severe head injury. A report from the NIH Traumatic Coma Data Bank. J Neurosurg. 1990;73(5):688-698. PMID: 2214049

28. Narayan RK, Greenberg RP, Miller JD, et al. Improved confidence of outcome prediction in severe head injury. A comparative analysis by the prognostic computerized tomography, clinical-multiple, and transcranial Doppler studies. J Neurosurg. 1981;54(6):751-762. PMID: 7228568

29. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. Lancet. 1974;2(7872):81-84. PMID: 4136544

30. Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the Glasgow Outcome Scale and the Extended Glasgow Outcome Scale: guidelines for their use. J Neurotrauma. 1998;15(8):573-585. PMID: 9748983

31. Hlatky R, Valadka AB, Robertson CS. Intracranial hypertension and cerebral ischemia after severe traumatic brain injury. Neurosurg Focus. 2003;14(2):e2. PMID: 12608849

32. Steiner LA, Andrews PJ. Monitoring the injured brain: ICP and CBF. Br J Anaesth. 2006;97(1):26-38. PMID: 16754524

33. Piper IR, Miller JD, Dearden NM, et al. Systems analysis of cerebrovascular pressure transmission: an observational study in head-injured patients. J Neurosurg. 1990;73(6):871-880. PMID: 2234883

34. Stocchetti N, Maas AI, Chieregato A, et al. Intracranial pressure monitoring in critically ill patients: when, how and why? Minerva Anestesiol. 2014;80(1):94-110. PMID: 24366519

35. Timofeev I, Czosnyka M, Nortje J, et al. Effect of decompressive craniectomy on intracranial pressure and cerebrospinal fluid circulation. J Neurosurg. 2008;108(1):66-73. PMID: 18176264

36. Morgalla MH, Krasznai L, Meinhardt A, et al. Comparison of silver-impregnated vs antibiotic-impregnated external ventricular drainage catheters. J Neurosurg. 2016;125(6):1500-1508. PMID: 26893271

37. Scheithauer S, Bürgel U, Ryang YM, et al. Prospective surveillance of drain associated meningitis/ventriculitis in a neurosurgery and neurological intensive care unit. J Neurol Neurosurg Psychiatry. 2009;80(12):1381-1385. PMID: 19666734

38. Williams TA, Leslie GD, Dobb GJ, et al. Complications of intracranial pressure monitoring in adults using a ventricular catheter. Anaesth Intensive Care. 1997;25(6):644-650. PMID: 9439860

39. Rughani AI, Dumont TM, Lu Z, et al. Use of ventriculostomy and external ventricular drain placement for intracerebral hemorrhage. J Neurosurg. 2012;116(4):789-794. PMID: 22132648

40. Naff NJ, Williams MA, Keyl PM, et al. Low-dose recombinant tissue-type plasminogen activator enhances clot resolution in brain hemorrhage: the intraventricular hemorrhage thrombolysis trial. Stroke. 2011;42(10):3009-3016. PMID: 21873602

41. Nieuwkamp DJ, de Gans K, Rinkel GJ, et al. Treatment and outcome of intraventricular hemorrhage. J Neurol. 2000;247(2):112-117. PMID: 10739873

42. Hallevy H, Herishanu Y. Evolving trends in the management of ventriculostomy associated infections. Curr Opin Infect Dis. 2018;31(4):325-330. PMID: 29702866

43. Lyke KE, Obasanjo OO, Williams MA, et al. Ventriculitis complicating use of intraventricular catheters in adult neurosurgical patients. Clin Infect Dis. 2001;33(12):2028-2033. PMID: 11740711

44. Dasic D, Hanna SJ, Boyd J, et al. Management of patients with intraventricular haemorrhage treated with external ventricular drainage: the impact of Glasgow Coma Scale on clinical outcome. Acta Neurochir Suppl. 2006;96:49-53. PMID: 17024430

45. Hoefnagel D, Dammers R, Ter Laak MP, et al. Risk factors for infections related to external ventricular drainage. Acta Neurochir (Wien). 2008;150(3):209-214. PMID: 18253888

46. Kim DK, Uttley D, Bell BA, et al. Comparison of trajectory and target accuracy between free-hand and electromagnetic neuronavigation-assisted catheter placement in the management of patients with intracerebral haemorrhage. Br J Neurosurg. 2009;23(6):627-632. PMID: 19929634

47. Huyette DR, Turnbow BJ, Kaufman C, et al. Accuracy of the freehand pass technique for ventriculostomy catheter placement. J Neurosurg. 2008;108(1):88-93. PMID: 18176263

48. Wilson TJ, Stetler WR Jr, Al-Holou WN, et al. Comparison of the accuracy of ventricular catheter placement using freehand placement, electromagnetic navigation, and ultrasound guidance. J Neurosurg. 2013;119(1):66-70. PMID: 23376949

49. Thomé C, Zieger A, Krauss JK, et al. Navigation-guided craniotomy for planning of correct trajectory of ventricular catheters. Neurosurg Rev. 2009;32(1):67-72. PMID: 18668230

50. Bekar A, Korfali E, Dogan S, et al. The effect of proton pump inhibitors on risk of intraventricular hemorrhage in external ventricular drainage. World Neurosurg. 2018;110:e100-e105. PMID: 29174073

51. Llompart-Pou JA, Pérez G, Raurich JM, et al. External ventricular drain infection during prolonged stay in the intensive care unit: a prospective analysis. J Neurosurg. 2011;114(1):194-200. PMID: 20704809

52. Van Dellen JR, Rose GC. A protocol for routine management of severe head injuries: cost analysis of external ventricular drainage. J Neurosurg. 1979;51(1):10-16. PMID: 447247

53. Prasad K, Mendelow AD, Gregson B. Surgery for primary supratentorial intracerebral haemorrhage. Cochrane Database Syst Rev. 2008;(4):CD000200. PMID: 18843684

54. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46(7):2032-2060. PMID: 26022637

55. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43(6):1711-1737. PMID: 22511724

56. Steiner T, Juvela S, Unterberg A, et al. European Stroke Organization guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke. 2014;9(7):840-855. PMID: 25302504

57. Neurocritical Care Society. Evidence-Based Guidelines for the Management of Large Hemispheric Infarction. Neurocrit Care. 2007;7(1):9-25. PMID: 17563312

58. Suarez JI, Tarr RW, Selman WR. Aneurysmal subarachnoid hemorrhage. N Engl J Med. 2006;354(4):387-396. PMID: 16436772

59. Frontera JA, Fernandez A, Schmidt JM, et al. Impact of nosocomial infectious complications after subarachnoid hemorrhage. Neurosurgery. 2008;62(1):80-87. PMID: 18162918

60. Wijdicks EF, Rabinstein AA. Absolutely no difference: antibiotic prophylaxis for ventricular catheters. Neurocrit Care. 2007;7(1):1-3. PMID: 17563298

61. Prabhu VC, Kaufman HH, Huoh K, et al. Intraventricular hemorrhage: the influence of the catheter type on the incidence of infection. Acta Neurochir (Wien). 1999;141(9):893-898. PMID: 10542828

62. Shapiro SA, Boaz J, Mehmood J, et al. The efficacy of antibiotic prophylaxis for the placement of external ventricular drains. Neurosurgery. 2006;59(3):688-695. PMID: 16954250

63. Holloway KL, Barnes T, Choi S, et al. Ventriculostomy infections: the effect of monitoring duration and catheter exchange in 584 patients. J Neurosurg. 1996;85(5):794-799. PMID: 8893628

64. Arabi Y, Memish ZA, Balkhy HH, et al. Ventriculostomy-associated infections: incidence and risk factors. Am J Infect Control. 2005;33(3):137-143. PMID: 15820346

65. Korinek AM, Reina M, Boch AL, et al. Prevention of external ventricular drain-related infectious complications by an antibiotic prophylaxis. Neurosurgery. 2005;57(5):1063-1065. PMID: 16281710

66. Patir R, Mahapatra AK, Banerji AK. Risk factors in postoperative neurosurgical infection. A prospective study. Acta Neurochir (Wien). 1992;119(1-4):80-84. PMID: 1596418

67. Sgouros S, Johnston P, Walsh A. Preoperative antibiotic prophylaxis for neurosurgical procedures: the need for standardization. Br J Neurosurg. 1997;11(2):131-134. PMID: 9170727

68. Blomstedt P. Postoperative complications in patients with external ventricular drainage. Acta Neurochir Suppl. 1985;36:53-56. PMID: 4035883

69. Friedmann R, Greif R, Berger K, et al. Ventriculostomy-associated infection: risk factors and clinical outcome. Zentralbl Neurochir. 2004;65(2):59-63. PMID: 15484603

70. Altschuler E, Moossy JJ, Shults WD, et al. The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with brain metastases. Neurosurgery. 1990;27(1):74-76. PMID: 2365091

71. Wartenberg KE, Schmidt JM, Claassen J, et al. Impact of medical complications on outcome after subarachnoid hemorrhage. Crit Care Med. 2006;34(3):617-624. PMID: 16484896

72. Claassen J, Peery S, Kreiter KT, et al. Predictors and clinical impact of epilepsy after subarachnoid hemorrhage. Arch Neurol. 2003;60(2):208-214. PMID: 12591884

73. Diringer MN, Bleck TP, Claude Hemphill J 3rd, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. Neurocrit Care. 2011;15(2):211-240. PMID: 21688194

74. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43(6):1711-1737. PMID: 22511724

75. Vergouwen MD, Ilodigwe D, Macdonald RL. Cerebral infarction after subarachnoid hemorrhage contributes to poor outcome by mortality and dependence. Stroke. 2011;42(6):1525-1530. PMID: 21527743

76. Wijdicks EF, Vermeulen M, van Gijn J. The importance of the level of consciousness in the grading of subarachnoid hemorrhage. Neurosurgery. 1988;22(5):968-971. PMID: 3383831

77. Rabinstein AA, Wijdicks EF. Cerebral aneurysm rebleeding after subarachnoid hemorrhage. Neurocrit Care. 2005;3(2):99-107. PMID: 16232986

78. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery. 1980;6(1):1-9. PMID: 7350801

79. Hijdra A, van Gijn J, Nagelkerke NJ, et al. Prediction of delayed cerebral ischemia, rebleeding, and outcome after aneurysmal subarachnoid hemorrhage. Stroke. 1988;19(10):1250-1256. PMID: 3172375

80. Kassell NF, Torner JC, Haley EC Jr, et al. The International Cooperative Study on the Timing of Aneurysm Surgery. Part 1: Overall management results. J Neurosurg. 1990;73(1):18-36. PMID: 2366980

81. Kassell NF, Torner JC, Jane JA, et al. The International Cooperative Study on the Timing of Aneurysm Surgery. Part 2: Surgical results. J Neurosurg. 1990;73(1):37-47. PMID: 2354258

82. Mayberg MR, Batjer HH, Dacey R, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 1994;25(11):2315-2328. PMID: 7945679

83. Roos YB, de Haan RJ, Beenen LF, et al. Complications and outcome in patients with aneurysmal subarachnoid haemorrhage: a prospective hospital based cohort study in the Netherlands. J Neurol Neurosurg Psychiatry. 2000;68(3):337-341. PMID: 10684730

84. Drake CG. Report of World Federation of Neurological Surgeons Committee on a universal subarachnoid hemorrhage grading scale. J Neurosurg. 1988;68(6):985-986. PMID: 3284947

85. van Gijn J, Bromberg JE, Lindsay KW, et al. Definition of initial grading used in randomized studies. In: Surgery for aneurysmal subarachnoid hemorrhage. Cochrane Database Syst Rev. 2005;(4):CD001947. PMID: 16235286

86. van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet. 2007;369(9558):306-318. PMID: 17258671

87. Ohman J, Heiskanen O. Timing of operation for ruptured supratentorial aneurysms: a prospective randomized study. J Neurosurg. 1989;70(1):55-60. PMID: 2909054

88. Torner JC, Kassell NF, Wallace RB, et al. Preoperative management of patients with aneurysmal subarachnoid hemorrhage: a cooperative study. J Neurosurg. 1981;54(2):215-219. PMID: 7210426

89. Wilkins RH. Aneurysm surgery during acute vasospasm. Clin Neurosurg. 1980;27:230-236. PMID: 7194672

90. Weir B, Disney L, Grace M. Size of aneurysm and risk of rebleeding. Acta Neurochir (Wien). 1987;82(1-2):39-43. PMID: 3619048